 Mark Steele
Concepts (270)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Idiopathic Pulmonary Fibrosis | 19 | 2023 | 500 | 2.950 |
Why?
| | Lung Diseases, Interstitial | 13 | 2023 | 495 | 2.040 |
Why?
| | Idiopathic Interstitial Pneumonias | 5 | 2019 | 46 | 1.150 |
Why?
| | Lung Transplantation | 14 | 2011 | 244 | 0.910 |
Why?
| | Lung | 17 | 2023 | 3521 | 0.620 |
Why?
| | Genetic Predisposition to Disease | 11 | 2019 | 2090 | 0.590 |
Why?
| | Mucin-5B | 7 | 2019 | 184 | 0.560 |
Why?
| | Biopsy | 10 | 2020 | 1024 | 0.500 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 2 | 2019 | 24 | 0.450 |
Why?
| | Machine Learning | 4 | 2019 | 315 | 0.450 |
Why?
| | Pulmonary Surfactant-Associated Protein C | 2 | 2019 | 42 | 0.440 |
Why?
| | Gene Expression Profiling | 5 | 2016 | 1519 | 0.380 |
Why?
| | Proteins | 1 | 2015 | 906 | 0.330 |
Why?
| | Transplants | 1 | 2008 | 36 | 0.300 |
Why?
| | Pulmonary Fibrosis | 6 | 2016 | 321 | 0.300 |
Why?
| | Middle Aged | 34 | 2021 | 26605 | 0.300 |
Why?
| | RNA | 2 | 2019 | 807 | 0.300 |
Why?
| | Sarcoma, Kaposi | 1 | 2008 | 68 | 0.300 |
Why?
| | Tissue Donors | 3 | 2011 | 314 | 0.290 |
Why?
| | Gene Expression Regulation | 2 | 2016 | 2321 | 0.290 |
Why?
| | Aged | 25 | 2021 | 18969 | 0.280 |
Why?
| | Polymorphism, Genetic | 4 | 2015 | 610 | 0.280 |
Why?
| | Bronchiolitis Obliterans | 5 | 2007 | 66 | 0.260 |
Why?
| | Genetic Variation | 4 | 2019 | 868 | 0.260 |
Why?
| | Mutation | 3 | 2012 | 3338 | 0.240 |
Why?
| | Biomarkers | 3 | 2020 | 3397 | 0.230 |
Why?
| | Case-Control Studies | 8 | 2019 | 3003 | 0.230 |
Why?
| | Tomography, X-Ray Computed | 8 | 2019 | 2272 | 0.230 |
Why?
| | Humans | 47 | 2023 | 114043 | 0.220 |
Why?
| | Male | 39 | 2021 | 55396 | 0.220 |
Why?
| | Reproducibility of Results | 4 | 2019 | 2764 | 0.200 |
Why?
| | ROC Curve | 4 | 2019 | 441 | 0.200 |
Why?
| | Female | 36 | 2021 | 59325 | 0.190 |
Why?
| | Dyspnea | 1 | 2023 | 212 | 0.190 |
Why?
| | Cohort Studies | 6 | 2023 | 4883 | 0.180 |
Why?
| | Coinfection | 1 | 2021 | 120 | 0.170 |
Why?
| | Cellular Senescence | 1 | 2019 | 151 | 0.150 |
Why?
| | DNA Helicases | 2 | 2019 | 133 | 0.150 |
Why?
| | Adult | 19 | 2021 | 30375 | 0.150 |
Why?
| | Incidence | 2 | 2023 | 2314 | 0.140 |
Why?
| | Genome-Wide Association Study | 4 | 2019 | 1176 | 0.140 |
Why?
| | Sequence Analysis, RNA | 2 | 2017 | 388 | 0.140 |
Why?
| | Bronchoscopy | 3 | 2015 | 196 | 0.140 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 319 | 0.140 |
Why?
| | Risk Factors | 9 | 2021 | 8614 | 0.130 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 295 | 0.130 |
Why?
| | Desmoplakins | 1 | 2016 | 19 | 0.130 |
Why?
| | HLA-DQ beta-Chains | 1 | 2016 | 57 | 0.130 |
Why?
| | Lung Neoplasms | 1 | 2008 | 2159 | 0.130 |
Why?
| | ADAMTS9 Protein | 1 | 2015 | 6 | 0.130 |
Why?
| | Serpin E2 | 1 | 2015 | 6 | 0.130 |
Why?
| | Procollagen N-Endopeptidase | 1 | 2015 | 8 | 0.130 |
Why?
| | HLA-DRB1 Chains | 1 | 2016 | 97 | 0.130 |
Why?
| | ADAMTS4 Protein | 1 | 2015 | 15 | 0.130 |
Why?
| | Cluster Analysis | 2 | 2014 | 452 | 0.130 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2015 | 29 | 0.130 |
Why?
| | Serpins | 1 | 2015 | 24 | 0.130 |
Why?
| | E-Selectin | 1 | 2015 | 52 | 0.130 |
Why?
| | Genetic Loci | 2 | 2016 | 262 | 0.130 |
Why?
| | ADAM Proteins | 1 | 2015 | 58 | 0.120 |
Why?
| | Carbon Monoxide | 2 | 2012 | 64 | 0.120 |
Why?
| | Influenza, Human | 1 | 2021 | 543 | 0.120 |
Why?
| | Algorithms | 2 | 2019 | 1469 | 0.120 |
Why?
| | Graft Rejection | 3 | 2007 | 511 | 0.120 |
Why?
| | Retrospective Studies | 10 | 2023 | 12521 | 0.120 |
Why?
| | Vital Capacity | 2 | 2012 | 254 | 0.120 |
Why?
| | Blood Cells | 1 | 2014 | 38 | 0.120 |
Why?
| | Radiography | 2 | 2008 | 803 | 0.120 |
Why?
| | Gene Frequency | 3 | 2015 | 476 | 0.110 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 250 | 0.110 |
Why?
| | RNA, Messenger | 3 | 2012 | 2550 | 0.110 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2015 | 388 | 0.100 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2012 | 742 | 0.100 |
Why?
| | Diagnosis, Differential | 4 | 2019 | 1331 | 0.100 |
Why?
| | Phenotype | 3 | 2015 | 2784 | 0.100 |
Why?
| | Scleroderma, Systemic | 1 | 2012 | 90 | 0.100 |
Why?
| | Promoter Regions, Genetic | 4 | 2019 | 1131 | 0.100 |
Why?
| | Sensitivity and Specificity | 4 | 2019 | 1690 | 0.100 |
Why?
| | Aged, 80 and over | 5 | 2021 | 6306 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 314 | 0.090 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2011 | 57 | 0.090 |
Why?
| | Gastroesophageal Reflux | 2 | 2003 | 229 | 0.090 |
Why?
| | Respiratory Function Tests | 3 | 2013 | 522 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 1815 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2014 | 2537 | 0.090 |
Why?
| | Pulmonary Surfactants | 2 | 2007 | 99 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 924 | 0.090 |
Why?
| | Postoperative Complications | 3 | 2006 | 2122 | 0.080 |
Why?
| | Transplantation, Homologous | 2 | 2008 | 377 | 0.080 |
Why?
| | Prognosis | 3 | 2012 | 3315 | 0.080 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2006 | 907 | 0.080 |
Why?
| | Gene Expression | 4 | 2017 | 1417 | 0.080 |
Why?
| | Herpesvirus 8, Human | 1 | 2008 | 61 | 0.080 |
Why?
| | Antibodies, Neoplasm | 1 | 2007 | 30 | 0.070 |
Why?
| | Fatal Outcome | 1 | 2008 | 281 | 0.070 |
Why?
| | Burkholderia cepacia | 1 | 2007 | 1 | 0.070 |
Why?
| | Burkholderia Infections | 1 | 2007 | 4 | 0.070 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2007 | 53 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2013 | 1880 | 0.070 |
Why?
| | Telomerase | 2 | 2019 | 205 | 0.070 |
Why?
| | Sirolimus | 1 | 2008 | 181 | 0.070 |
Why?
| | Doxorubicin | 1 | 2008 | 286 | 0.070 |
Why?
| | Disease Progression | 2 | 2012 | 2371 | 0.070 |
Why?
| | Viral Load | 1 | 2008 | 405 | 0.070 |
Why?
| | Drug Resistance, Bacterial | 1 | 2007 | 156 | 0.070 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2007 | 57 | 0.070 |
Why?
| | Prevalence | 3 | 2021 | 2247 | 0.070 |
Why?
| | Smoking | 3 | 2013 | 1382 | 0.060 |
Why?
| | Chromosome Mapping | 1 | 2007 | 486 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 641 | 0.060 |
Why?
| | Empyema | 1 | 2004 | 4 | 0.060 |
Why?
| | Ganciclovir | 1 | 2004 | 48 | 0.060 |
Why?
| | Aspergillus fumigatus | 1 | 2004 | 20 | 0.060 |
Why?
| | Aspergillosis | 1 | 2004 | 23 | 0.060 |
Why?
| | Genotype | 3 | 2013 | 1757 | 0.060 |
Why?
| | HLA Antigens | 1 | 2005 | 220 | 0.060 |
Why?
| | Opportunistic Infections | 1 | 2004 | 43 | 0.060 |
Why?
| | Sequence Analysis, DNA | 2 | 2019 | 722 | 0.050 |
Why?
| | Logistic Models | 2 | 2019 | 1829 | 0.050 |
Why?
| | Arthritis, Infectious | 1 | 2004 | 49 | 0.050 |
Why?
| | Linkage Disequilibrium | 2 | 2016 | 245 | 0.050 |
Why?
| | Lymphoproliferative Disorders | 1 | 2003 | 46 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 365 | 0.050 |
Why?
| | Triazoles | 1 | 2004 | 125 | 0.050 |
Why?
| | Fundoplication | 1 | 2003 | 51 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2023 | 94 | 0.050 |
Why?
| | Exome | 1 | 2023 | 200 | 0.050 |
Why?
| | Lung Injury | 1 | 2004 | 192 | 0.050 |
Why?
| | Cytomegalovirus Infections | 1 | 2004 | 180 | 0.050 |
Why?
| | Age Factors | 2 | 2006 | 2885 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2007 | 1257 | 0.050 |
Why?
| | Paramyxoviridae Infections | 1 | 2021 | 10 | 0.050 |
Why?
| | Survival Analysis | 3 | 2013 | 1206 | 0.050 |
Why?
| | Metapneumovirus | 1 | 2021 | 12 | 0.050 |
Why?
| | Rhinovirus | 1 | 2021 | 40 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 1791 | 0.050 |
Why?
| | Picornaviridae Infections | 1 | 2021 | 29 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2007 | 3498 | 0.040 |
Why?
| | Activin Receptors, Type I | 1 | 2000 | 9 | 0.040 |
Why?
| | Sex Factors | 1 | 2005 | 1706 | 0.040 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2000 | 52 | 0.040 |
Why?
| | Tracheal Diseases | 1 | 2000 | 13 | 0.040 |
Why?
| | Bronchial Diseases | 1 | 2000 | 35 | 0.040 |
Why?
| | Amyloidosis | 1 | 2000 | 36 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2004 | 614 | 0.040 |
Why?
| | Forced Expiratory Volume | 3 | 2007 | 471 | 0.040 |
Why?
| | GTPase-Activating Proteins | 1 | 2019 | 72 | 0.040 |
Why?
| | Exoribonucleases | 1 | 2019 | 40 | 0.040 |
Why?
| | Pedigree | 2 | 2015 | 460 | 0.040 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2019 | 122 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2004 | 642 | 0.040 |
Why?
| | Enterovirus Infections | 1 | 2021 | 160 | 0.040 |
Why?
| | Telomere-Binding Proteins | 1 | 2019 | 88 | 0.040 |
Why?
| | Young Adult | 3 | 2021 | 10444 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2007 | 1471 | 0.040 |
Why?
| | Cystic Fibrosis | 1 | 2007 | 955 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 2 | 2012 | 813 | 0.040 |
Why?
| | Prospective Studies | 3 | 2019 | 6195 | 0.040 |
Why?
| | Fibrosis | 1 | 2020 | 452 | 0.040 |
Why?
| | Physicians | 1 | 2006 | 765 | 0.040 |
Why?
| | Adolescent | 5 | 2021 | 17800 | 0.040 |
Why?
| | Survival Rate | 3 | 2007 | 1638 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 437 | 0.030 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2016 | 44 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2021 | 326 | 0.030 |
Why?
| | Herpesviridae | 1 | 2015 | 21 | 0.030 |
Why?
| | Syndrome | 2 | 2006 | 330 | 0.030 |
Why?
| | Bronchoalveolar Lavage | 1 | 2015 | 82 | 0.030 |
Why?
| | Asbestos | 1 | 1994 | 19 | 0.030 |
Why?
| | Ferric Compounds | 1 | 1994 | 41 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2015 | 75 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 250 | 0.030 |
Why?
| | Phagocytes | 1 | 1994 | 90 | 0.030 |
Why?
| | Animals | 6 | 2007 | 31565 | 0.030 |
Why?
| | Bleomycin | 2 | 2006 | 228 | 0.030 |
Why?
| | Mice | 2 | 2007 | 14841 | 0.030 |
Why?
| | Genetic Markers | 1 | 2015 | 320 | 0.030 |
Why?
| | Treatment Outcome | 5 | 2007 | 9049 | 0.030 |
Why?
| | United States | 3 | 2021 | 12137 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 951 | 0.030 |
Why?
| | Total Lung Capacity | 1 | 2013 | 30 | 0.030 |
Why?
| | Chromosomes, Human | 1 | 2013 | 39 | 0.030 |
Why?
| | DNA, Viral | 1 | 2015 | 349 | 0.030 |
Why?
| | Telomere | 1 | 2015 | 202 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2003 | 507 | 0.020 |
Why?
| | Observer Variation | 1 | 2012 | 298 | 0.020 |
Why?
| | Wasp Venoms | 1 | 1991 | 4 | 0.020 |
Why?
| | Area Under Curve | 1 | 2011 | 273 | 0.020 |
Why?
| | Risk | 1 | 2013 | 810 | 0.020 |
Why?
| | Aging | 1 | 2000 | 1611 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2011 | 294 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4090 | 0.020 |
Why?
| | Bayes Theorem | 1 | 2011 | 327 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 945 | 0.020 |
Why?
| | Pulmonary Alveoli | 1 | 1991 | 372 | 0.020 |
Why?
| | CD52 Antigen | 1 | 2007 | 3 | 0.020 |
Why?
| | Alemtuzumab | 1 | 2007 | 12 | 0.020 |
Why?
| | Ontario | 1 | 2007 | 77 | 0.020 |
Why?
| | North Carolina | 1 | 2007 | 83 | 0.020 |
Why?
| | Colony Count, Microbial | 1 | 2007 | 111 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2384 | 0.020 |
Why?
| | Chemokines, CXC | 1 | 2006 | 60 | 0.020 |
Why?
| | Chemokine CXCL12 | 1 | 2006 | 74 | 0.020 |
Why?
| | Receptors, CXCR4 | 1 | 2006 | 78 | 0.020 |
Why?
| | Antigens, Neoplasm | 1 | 2007 | 222 | 0.020 |
Why?
| | Glycoproteins | 1 | 2007 | 304 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2005 | 43 | 0.020 |
Why?
| | Wnt Proteins | 1 | 2006 | 134 | 0.020 |
Why?
| | Blood Grouping and Crossmatching | 1 | 2005 | 16 | 0.020 |
Why?
| | Antigens, CD | 1 | 2007 | 440 | 0.020 |
Why?
| | APACHE | 1 | 2004 | 58 | 0.010 |
Why?
| | Reoperation | 1 | 2006 | 513 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 2004 | 198 | 0.010 |
Why?
| | Rats | 3 | 2000 | 4913 | 0.010 |
Why?
| | Periodicals as Topic | 1 | 2006 | 180 | 0.010 |
Why?
| | Maximal Expiratory Flow Rate | 1 | 2003 | 3 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 2003 | 21 | 0.010 |
Why?
| | Gastric Acidity Determination | 1 | 2003 | 7 | 0.010 |
Why?
| | Epidemiological Monitoring | 1 | 2003 | 46 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2007 | 660 | 0.010 |
Why?
| | Antifungal Agents | 1 | 2004 | 128 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2004 | 143 | 0.010 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2004 | 122 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 2 | 2000 | 2182 | 0.010 |
Why?
| | Immunocompromised Host | 1 | 2004 | 192 | 0.010 |
Why?
| | Wound Healing | 1 | 2004 | 254 | 0.010 |
Why?
| | Administration, Oral | 1 | 2004 | 725 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2007 | 959 | 0.010 |
Why?
| | Environmental Monitoring | 1 | 2003 | 255 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2006 | 2562 | 0.010 |
Why?
| | Blotting, Northern | 1 | 2000 | 193 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 2000 | 94 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 2004 | 528 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2003 | 1078 | 0.010 |
Why?
| | Fibroblasts | 1 | 2004 | 834 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2000 | 292 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2000 | 285 | 0.010 |
Why?
| | Length of Stay | 1 | 2004 | 957 | 0.010 |
Why?
| | Cells, Cultured | 2 | 2000 | 3861 | 0.010 |
Why?
| | Patient Readmission | 1 | 2004 | 607 | 0.010 |
Why?
| | Animals, Newborn | 1 | 2000 | 777 | 0.010 |
Why?
| | Airway Obstruction | 1 | 2000 | 160 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1611 | 0.010 |
Why?
| | Calcium | 2 | 1994 | 1089 | 0.010 |
Why?
| | Fetus | 1 | 2000 | 698 | 0.010 |
Why?
| | Asbestos, Crocidolite | 1 | 1994 | 1 | 0.010 |
Why?
| | Respiratory Burst | 1 | 1994 | 16 | 0.010 |
Why?
| | Chelating Agents | 1 | 1994 | 61 | 0.010 |
Why?
| | Magnesium | 1 | 1994 | 144 | 0.010 |
Why?
| | Inflammation | 1 | 2004 | 2464 | 0.010 |
Why?
| | Epithelium | 1 | 1994 | 295 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 6077 | 0.010 |
Why?
| | Superoxide Dismutase | 1 | 1994 | 305 | 0.010 |
Why?
| | Heart Failure | 1 | 2005 | 1958 | 0.010 |
Why?
| | Macrophages, Alveolar | 1 | 1994 | 348 | 0.010 |
Why?
| | Virulence Factors, Bordetella | 1 | 1991 | 19 | 0.010 |
Why?
| | Inositol Phosphates | 1 | 1991 | 23 | 0.010 |
Why?
| | Pertussis Toxin | 1 | 1991 | 24 | 0.010 |
Why?
| | Guanine Nucleotides | 1 | 1991 | 15 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2000 | 4392 | 0.010 |
Why?
| | Arachidonic Acids | 1 | 1991 | 56 | 0.010 |
Why?
| | Type C Phospholipases | 1 | 1991 | 65 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1991 | 360 | 0.010 |
Why?
| | Cyclic AMP | 1 | 1991 | 225 | 0.010 |
Why?
| | Neutrophils | 1 | 1994 | 1089 | 0.010 |
Why?
| | Protein Kinase C | 1 | 1991 | 271 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 1991 | 347 | 0.010 |
Why?
| | Oxidative Stress | 1 | 1994 | 1068 | 0.000 |
Why?
| | Kinetics | 1 | 1991 | 1547 | 0.000 |
Why?
| | Peptides | 1 | 1991 | 848 | 0.000 |
Why?
|
|
Steele's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|